Stocktoria
Apyx Medical Corp APYX
Apyx Medical Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.8M | $48.1M | $52.3M | $44.5M | $48.5M | $27.7M | $28.2M | $16.7M | $10.2M | $8.8M |
| Gross profit | $33.0M | $29.4M | $33.8M | $29.1M | $33.6M | $17.5M | $19.1M | $10.8M | $7.0M | $5.1M |
| R&D expense | $3.4M | $5.1M | $5.4M | $4.5M | $4.3M | $3.9M | $3.7M | $2.5M | $1.9M | $1.0M |
| SG&A expense | $15.8M | $18.9M | $22.2M | $20.5M | $18.6M | $11.7M | $13.7M | $9.4M | $8.7M | $6.2M |
| Operating income | -$6.4M | -$18.8M | -$17.3M | -$23.6M | -$14.4M | -$20.1M | -$20.9M | -$14.3M | -$13.9M | -$11.4M |
| Interest expense | — | — | $2.5M | $15,000 | $10,000 | $46,000 | $8,000 | $104,000 | $136,000 | $158,000 |
| Income tax | $270,000 | $252,000 | -$2.4M | $367,000 | $380,000 | -$7.5M | -$130,000 | -$3.9M | -$156,000 | $64,000 |
| Net income | -$11.2M | -$23.5M | -$18.7M | -$23.2M | -$15.2M | -$11.9M | -$19.7M | $62.7M | -$5.1M | -$11.6M |
| EPS (diluted) | — | — | $-0.54 | $-0.67 | $-0.44 | $-0.35 | $-0.58 | $1.83 | $-0.17 | $-0.15 |
| Operating cash flow | -$8.0M | -$18.0M | -$5.2M | -$20.3M | -$10.4M | -$16.1M | -$18.5M | -$20.9M | -$3.7M | -$2.8M |
| Free cash flow | -$9.1M | -$18.8M | -$5.8M | -$21.3M | -$11.2M | -$16.6M | -$19.8M | -$21.2M | -$4.3M | -$3.1M |
| Cash & equivalents | $31.7M | $31.7M | $43.7M | $10.2M | $30.9M | $41.9M | $58.8M | $16.6M | $9.9M | $14.5M |
| Inventory | $8.6M | $7.6M | $9.9M | $11.8M | $6.8M | $4.1M | $5.1M | $3.1M | $4.3M | $6.2M |
| Total assets | $66.8M | $64.8M | $79.2M | $51.8M | $68.7M | $74.1M | $84.7M | $95.9M | $31.0M | $35.1M |
| Total liabilities | $52.0M | $50.5M | $52.3M | $14.0M | $14.7M | $10.3M | $13.5M | $8.8M | $9.0M | $8.9M |
| Shareholders' equity | $14.8M | $14.3M | $26.9M | $37.8M | $54.0M | $63.9M | $71.3M | $87.2M | $22.0M | $26.2M |
Growth · year-over-year · Revenue CAGR 22%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +9.9% | -8.1% | +17.6% | -8.3% | +75.1% | -1.9% | +69.2% | +63.0% | +16.0% | -70.1% |
| Net income growth | — | — | — | — | — | — | -131.4% | — | — | — |
| EPS growth | — | — | — | — | — | — | -131.7% | — | — | -162.5% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.